CyberKnife Stereotactic Body Radiation Therapy for Small Hepatocellular Carcinoma Patients With Decompensated Cirrhosis

Recruiting now

Conditions studied: Hepatocellular Carcinoma

In brief

The aim of our research is to evaluate the curative effect and safety of CyberKnife stereotactic body radiation therapy in treating small hepatocellular carcinoma (HCC) patients with decompensated cirrhosis.

Key facts

Study ID

NCT04512833

Run by

Beijing 302 Hospital

People needed

60

Starts

2020-08-12

Expected to finish

2026-08-30

Last updated by the study team

2023-06-27

Who can join

Age: 30 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Primary HCC diagnosed by a surgeon and/or radiologist and oncologist according to the international guidelines for the management of HCC or by pathology
• Unfeasible or refusing to undergo other treatments;
• Residual normal liver volume ≥700 cc;
• With decompensated cirrhosis (Child-Pugh B or C classification);
• Without portal vein tumor thrombus;
• Eastern Cooperative Oncology Group (ECOG) score 0-1;
• Distances between tumor and normal organs (esophagus, stomach, duodenum, bowel) are more than 5 mm；
• Rejecting other therapies such as resection, liver transplantation, etc.
• Platelet count≥50 × 109/L, white blood count≥1.5 × 109/L;
• Patients infected with hepatitis B virus who are treated with adefovir or entecavir; patients infected with hepatitis C virus whose HCV DNA are negative.

You may not qualify if…

• With Tumor thrombus；
• With extrahepatic metastasis;
• With lymph node involvement.

Where it is running

• Beijing 302 hospital — Beijing, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.